Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

Advanced chronic liver disease (ACLD) is a serious public health issue for which a safe and effective treatment is still lacking. It is often associated with portal hypertension and liver fibrosis. Over the recent years, peroxisome proliferator-activated receptors family (PPARs) have been considered as a relevant...
PUBLISHED IN: J Hepatol 2020

Commentary

Advanced chronic liver disease (ACLD) is a serious public health issue for which a safe and effective treatment is still lacking. It is often associated with portal hypertension and liver fibrosis.

Over the recent years, peroxisome proliferator-activated receptors family (PPARs) have been considered as a relevant therapeutic option. Z Boyer-Diaz et al. tried to evaluate the therapeutic potential of pan-PPAR activation for the treatment of advanced cirrhosis.

This study demonstrated for the first time that lanifibranor exerts beneficial effects in a pre-clinical model of decompensated cirrhosis, leading to a marked improvement of fibrosis and portal hypertension.

Evaluation of lanifibranor in liver cells from patients suffering from ACLD further supports its beneficial effects. This should encourage further clinical evaluation of lanifibranor for the treatment of ACLD and portal hypertension.

Share the article
Dr. G. Bozet, MD

Dr. G. Bozet, MD

Articles: 174

Leave a Reply

Your email address will not be published.